Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Gains from Investment Securities (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Gains from Investment Securities for 5 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $7.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.6 million, a N/A change, with the full-year FY2025 number at $6.9 million, up 6739.6% from a year prior.
  • Gains from Investment Securities was $7.9 million for Q4 2025 at Relay Therapeutics, up from -$7.9 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $7.9 million in Q4 2025 to a low of -$7.9 million in Q3 2025.
  • A 4-year average of $69535.0 and a median of $1.5 million in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 131.05% in 2021, then skyrocketed 132.92% in 2023.
  • Relay Therapeutics' Gains from Investment Securities stood at -$900000.0 in 2021, then tumbled by 410.56% to -$4.6 million in 2022, then surged by 132.92% to $1.5 million in 2023, then surged by 420.62% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Gains from Investment Securities are $7.9 million (Q4 2025), -$7.9 million (Q3 2025), and $1.5 million (Q4 2023).